| Literature DB >> 30315348 |
Aliyah M Weinstein1,2,3,4,5, Nicolas A Giraldo6,7,8,9, Florent Petitprez6,7,8,10, Catherine Julie11,12, Laetitia Lacroix6,7,8, Frédérique Peschaud11,12, Jean-François Emile11,12, Laetitia Marisa10, Wolf H Fridman6,7,8, Walter J Storkus13,14,15,16, Catherine Sautès-Fridman6,7,8.
Abstract
IL-1 family cytokines play a dual role in the gut, with different family members contributing either protective or pathogenic effects. IL-36γ is an IL-1 family cytokine involved in polarizing type-1 immune responses. However, its function in the gut, including in colorectal cancer pathogenesis, is not well appreciated. In a murine model of colon carcinoma, IL-36γ controls tertiary lymphoid structure formation and promotes a type-1 immune response concurrently with a decrease in expression of immune checkpoint molecules in the tumor microenvironment. Here, we demonstrate that IL-36γ plays a similar role in driving a pro-inflammatory phenotype in human colorectal cancer. We analyzed a cohort of 33 primary colorectal carcinoma tumors using imaging, flow cytometry, and transcriptomics to determine the pattern and role of IL-36γ expression in this disease. In the colorectal tumor microenvironment, we observed IL-36γ to be predominantly expressed by M1 macrophages and cells of the vasculature, including smooth muscle cells and high endothelial venules. This pattern of IL-36γ expression is associated with a CD4+ central memory T cell infiltrate and an increased density of B cells in tertiary lymphoid structures, as well as with markers of fibrosis. Conversely, expression of the antagonist to IL-36 signaling, IL-1F5, was associated with intratumoral expression of checkpoint molecules, including PD-1, PD-L1, and CTLA4, which can suppress the immune response. These data support a role for IL-36γ in the physiologic immune response to colorectal cancer by sustaining inflammation within the tumor microenvironment.Entities:
Keywords: Colorectal cancer; Interleukin (IL)-36 g; M1 classically activated macrophages; Memory T cells; Tertiary lymphoid structure
Mesh:
Substances:
Year: 2018 PMID: 30315348 PMCID: PMC7185158 DOI: 10.1007/s00262-018-2259-0
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968